Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sequana Medical NV
< Previous
1
2
Next >
Sequana Medical granted US CPT® III reimbursement codes for alfapump® system
January 03, 2024
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical submits Premarket Approval application to US FDA for alfapump® in recurrent or refractory ascites due to liver cirrhosis
December 28, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure
November 29, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces results of Extraordinary General Meeting of Shareholders
November 10, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission
October 19, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome
October 18, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces H1 2023 results and provides business update
September 14, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical Notice of 2023 Half-year Results and Business Update
September 06, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
July 10, 2023
From
Sequana Medical NV
Via
GlobeNewswire
1,000th alfapump® implant completed
July 06, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces results of Special General Meeting of Shareholders
June 26, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON)
June 21, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Additional data from North American pivotal alfapump® study (POSEIDON) will be presented at EASL Congress 2023
June 19, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical wins Best Technology Award for alfapump® at European Mediscience Awards
June 16, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces Special General Meeting of Shareholders on 26 June 2023
May 26, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces results of Annual General Meeting of Shareholders
May 25, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Transparency Notifications from Shareholders
May 15, 2023
From
Sequana Medical NV
Via
GlobeNewswire
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
May 10, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure
May 02, 2023
From
Sequana Medical NV
Via
GlobeNewswire
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
April 27, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure
April 03, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces additional patents for DSR® in China and the United States
March 22, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure
March 01, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces results of Extraordinary General Meeting of Shareholders
February 10, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces 2022 Full Year Results and 2023 Outlook
February 09, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Transparency Notifications from Shareholders
February 09, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure
February 08, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical Notice of 2022 Full Year Results and Business Update
February 02, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces grant of additional DSR® patent in United States
February 01, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 February 2023
January 11, 2023
From
Sequana Medical NV
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.